Literature DB >> 11212115

Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.

L L Brockunier1, M R Candelore, M A Cascieri, Y Liu, L Tota, M J Wyvratt, M H Fisher, A E Weber, E R Parmee.   

Abstract

Pyridineethanolamine derivatives containing cyanoguanidine or nitroethylenediamine moieties were examined as human beta3 adrenergic receptor (AR) agonists. Notably, indoline derivatives 6a and 11 were potent beta3 AR agonists (beta3 EC50 = 13 and 19 nM, respectively), which showed good selectivity over binding to and minimal activation of the beta1 and beta2 ARs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212115     DOI: 10.1016/s0960-894x(00)00669-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Insights into the binding modes of human β₃-adrenergic receptor agonists with ligand-based and receptor-based methods.

Authors:  Fangfang Jin; Chunhua Lu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  Mol Divers       Date:  2011-03-20       Impact factor: 2.943

3.  Characterization of beta3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for beta3 adrenergic receptor agonism.

Authors:  Philip Prathipati; Anil K Saxena
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

4.  Signaling pathways mediating beta3-adrenergic receptor-induced production of interleukin-6 in adipocytes.

Authors:  Inna E Tchivileva; Kai Soo Tan; Maria Gambarian; Andrea G Nackley; Alexander V Medvedev; Sergei Romanov; Patrick M Flood; William Maixner; Sergei S Makarov; Luda Diatchenko
Journal:  Mol Immunol       Date:  2009-05-23       Impact factor: 4.407

5.  Pharmacophore-guided Virtual Screening to Identify New β3 -adrenergic Receptor Agonists.

Authors:  Navista Sri Octa Ujiantari; Seungmin Ham; Chisae Nagiri; Wataru Shihoya; Osamu Nureki; Dana Sabine Hutchinson; Daniela Schuster
Journal:  Mol Inform       Date:  2022-02-02       Impact factor: 4.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.